Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMI7DZ2)

• Drug Name: Prilocaine Drug Info
• Synonyms: Citanest; Prilocaina; Prilocainum; Propitocaine; Prilocaine [USAN]; Prilocaine base; Astra 1512; Astra 1515; L 67; Citanest (TN); Prilocaina [INN-Spanish]; Prilocainum [INN-Latin]; Propitocaine (JAN); Prilocaine (USP/INN); O-Methyl-2-propylaminopropionanilide; O-Methyl-alpha-propylaminopropionanilide; Alpha-n-Propylamino-2-methylpropionanilide; N-[2-Methylphenyl]-2-[propylamino]propanamide; N-(2-methylphenyl)-N2-propylalaninamide; N-(2-Methylphenyl)-2-(propylamino)propanamide; N-(2-methylphenyl)-N(2)-propylalaninamide; Propanamide, N-(2-methylphenyl)-2-(propylamino)-(9CI); 2-(Propylamino)-o-propionotoluidide; 2-Methyl-.alpha.-propylaminopropionanilide; 2-Methyl-alpha-propylaminopropionanilide
• Therapeutic Class: Anesthetics
• Cross-matching ID:
  PubChem CID: 4906
  ChEBI ID: CHEMBL1194
  CAS Number: CAS 721-50-6
  TTD Drug ID: D06LYG

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Proteasome	2.10	0.00e+0	44/46 (95.65%)	PSMD6;PSMA1;PSMD2;...
Parkinson disease	2.09	0.00e+0	176/249 (70.68%)	MAP3K5;TUBB;PSMD6;...
Glyoxylate and dicarboxylate metabolism	2.08	0.00e+0	23/30 (76.67%)	MDH2;DLD;SHMT1;...
Oxidative phosphorylation	2.06	0.00e+0	93/133 (69.92%)	ATP6V1D;ATP5F1B;COX6A2;...
Citrate cycle (TCA cycle)	1.99	1.67e-3	30/30 (100%)	MDH2;DLD;SUCLG2;...
Pyruvate metabolism	1.92	5.56e-3	41/47 (87.23%)	MDH2;DLD;ACAT2;...
Retinol metabolism	1.85	8.33e-3	41/68 (60.29%)	ALDH1A3;UGT2B28;AOX1;...
Ascorbate and aldarate metabolism	1.84	7.29e-3	15/30 (50%)	UGT2B28;UGT2A3;UGT2B17;...
Porphyrin and chlorophyll metabolism	1.81	1.11e-2	23/43 (53.49%)	UGT2B28;CP;ALAS2;...
Prion disease	1.73	3.25e-2	209/273 (76.56%)	TUBB;PSMD6;PSMA1;...
Huntington disease	1.72	2.95e-2	233/306 (76.14%)	MAP3K5;TUBB;GRIA2;...
Aminoacyl-tRNA biosynthesis	1.71	3.06e-2	15/66 (22.73%)	IARS2;QRSL1;SARS2;...
Diabetic cardiomyopathy	1.65	4.55e-2	162/203 (79.8%)	ATP5F1B;PLCB1;VDAC1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H	Show ▼